Halozyme Therapeutics Inc Dossier - Source-backed chat

Halozyme Therapeutics Inc

HALONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.90

Intrinsic Value $154.92median of 6 methods · middle span $64-$1,125based on filings through 30 Jun 2026

Market Price $106.94Price as of 1 Oct 2026

UndervaluedIntrinsic value is 45% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $12.1B

Enterprise Value $14.1B

Shares Outstanding 120.5M diluted

Moat Rating Wide

Next Earnings Date2 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Halozyme entered the second half of 2026 with strong operating momentum: second-quarter royalty revenue increased 50% year over year, total revenue increased 48%, full-year guidance was raised, and five new ENHANZE or Hypercon collaborations had been signed through July. The portfolio now combines commercially validated ENHANZE economics with Hypercon and Surf Bio hyperconcentration technologies carrying intellectual-property duration into the mid-2040s. Offsetting these merits are dependence on partners' product performance and development execution, intellectual-property litigation, acquisition integration, and policy uncertainty.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$70.00

Mean target$99.56

High · most bullish analyst$115.00

Street targets sit below today's price; our intrinsic value sits above it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$70.0018%

Partner-product uptake or API sales weaken enough to put the lower ends of 2026 guidance at risk, while acquired-platform spending, development delays, intellectual-property disputes, or adverse pricing-policy changes reduce confidence in the durability and timing of future royalty streams.

Base CaseCentral scenario

$99.5658%

Matches the consensus mean

Halozyme delivers within its raised 2026 ranges, with royalty growth remaining the primary earnings driver and investments in Hypercon and Surf Bio progressing without materially disrupting profitability. New collaborations replenish the longer-term pipeline, but partner-controlled development timelines and litigation keep the risk-adjusted outlook balanced.

Bull CaseUpside scenario

$115.0024%

Royalty revenue finishes near or above the upper end of the raised 2026 range as DARZALEX SC, VYVGART Hytrulo, and other launched partner products maintain strong uptake. The five collaborations signed through July produce additional development starts, while Hypercon and Surf Bio broaden the addressable set of biologics and extend royalty duration into the 2040s.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-quarter 2026 royalty revenue increased 50% year over year to USD 307.7 million, supporting raised full-year royalty-revenue guidance of USD 1.220-1.245 billion.
Halozyme signed five ENHANZE and Hypercon collaboration agreements through July 2026, exceeding its original full-year goal of three.
Hypercon and Surf Bio expand the subcutaneous-delivery opportunity beyond ENHANZE, and Halozyme states that the acquired technologies have intellectual-property duration into the mid-2040s.

Key Investment Risks

Royalty performance depends substantially on partners' commercialization, clinical-development, regulatory, and launch execution; Halozyme identified VYVGART Hytrulo and DARZALEX SC as predominant contributors to recent royalty growth.
Patent enforcement remains active and uncertain: proceedings involving Merck's subcutaneous Keytruda include U.S. litigation and European patent challenges, even though Halozyme states that the MDASE dispute is distinct from ENHANZE licensing.
Policy conclusions remain provisional because Halozyme's projection of zero-to-minimal Medicare negotiation impact through at least 2035 was based on a proposed CMS rule and stated assumptions.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.